NueVistraMed

NueVistraMed is a pharmaceutical distribution and healthcare ecosystem company that bridges the gap between scientific breakthroughs and clinical application. The company operates an institutional platform serving over 1,850 digital and physical clinics, providing them with collective buying power and priority access to wellness pharmaceuticals. Its product portfolio features inhalED, a proprietary dry-powder sildenafil inhaler for rapid-onset treatment of erectile dysfunction, alongside accessible testosterone therapies produced through strategic 503B compounding partnerships. In 2026, NueVistraMed was acquired by NexTel Medical Corp to serve as a primary commercialization channel for advanced exosome-based diagnostics and therapeutics.